Xcout Intel
MaaT Pharma
MaaT Pharma is a clinical-stage biotechnology company that develops microbiome-based therapeutics to improve treatment outcomes and survival rates for cancer patients. The company focuses on restoring microbiome function to address life-threatening diseases using a full ecosystem approach and AI-powered drug development.
Subscribe to see MaaT Pharma’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
MaaT Pharma at a glance
MaaT Pharma is a biotech company headquartered in France. Xcout tracks 12 named people at MaaT Pharma, including ERIC SOYER (Chief Financial Officer).
MaaT Pharma leadership
- ERIC SOYERChief Financial Officer
- Carole SchwintnerChief Technology Officer
- Emilie PlantamuraDeputy Chief Medical Officer
- Frédéric FasanoChief Strategy & Corporate Development Officer
- Sheri SimmonsActing Chief Scientific Officer
- Hervé AffagardCEO and co-founder
6 more named people on record for MaaT Pharma, with roles, board committees and tenure — see the full roster →
MaaT Pharma competitors
A few of MaaT Pharma's closest competitors — see the full list of competitors and alternatives →
T3 Pharmaceuticals AG is a biotechnology company that develops a proprietary technology platform utilizing bacteria to deliver targeted therapies. The company focuses on advancing a pipeline of Immuno-Oncology products designed to treat cancer patients.
Exeliom Biosciences is a clinical-stage biopharmaceutical company headquartered in France that develops novel therapeutic approaches harnessing microbiome-host interactions.
ME Therapeutics Holdings Inc. is a clinical-stage biotechnology company that discovers and develops immuno-oncology therapeutics designed to reprogram immune cells in vivo. Its pipeline aims to activate the body's immune system to recognize and fight cancer cells.
MAIA Biotechnology, Inc. is a clinical-stage biotech firm dedicated to discovering, developing, and commercializing treatments for various cancers, with a primary focus on non-small cell lung cancer. The company's leading experimental compound, THIO, is an investigational drug candidate that utilizes a unique dual mechanism by targeting telomeres and stimulating an immune response. Established in 2018, the enterprise maintains its headquarters in Chicago, Illinois.
Laguna Pharmaceuticals is a biotechnology company developing precision microbial immunotherapy platforms to treat various cancers, including high-risk leukemias and soft-tissue sarcomas. The company utilizes engineered, highly attenuated microbial vectors to activate and expand innate T cells directly within the body, aiming to overcome immune evasion by tumors.
Surface Oncology is a clinical-stage biotechnology company focused on developing immunotherapies that target the tumor microenvironment and enhance anti-tumor immune responses. Its programs are intended for cancer patients and are developed for use by oncology physicians and healthcare systems, with potential pharmaceutical partnerships.
Get MaaT Pharma's news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on MaaT Pharma in Xcout Intel
- 12 named people with titles, LinkedIn and board committees
- The full competitor set, tracking, exports and API access